Using radiologic response to predict prognosis in patients with muscle-invasive bladder cancer undergoing carboplatin-based neoadjuvant chemotherapy

被引：0
|
作者：
Hatakeyama, Shingo [1 ]
Yamamoto, Hayato [1 ]
Okamoto, Akiko [1 ]
Imai, Atsushi [1 ]
Yoneyama, Takahiro [1 ]
Hashimoto, Yasuhiro [1 ]
Koie, Takuya [1 ]
Ohyama, Chikara [1 ]
机构：
[1] Hirosaki Univ, Dept Urol, Grad Sch Med, Hirosaki, Aomori, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.361
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
361
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CARBOPLATIN-BASED CHEMOTHERAPY FOR BLADDER-CANCER
    WAXMAN, J
    BARTON, C
    CANCER TREATMENT REVIEWS, 1993, 19 : 21 - 25
  • [42] The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer
    Stecca, Carlos
    Mitin, Timur
    Sridhar, Srikala S.
    SEMINARS IN RADIATION ONCOLOGY, 2023, 33 (01) : 51 - 55
  • [43] Carboplatin-based chemotherapy in patients undergoing hemodialysis
    Yanagawa, H
    Takishita, Y
    Bando, H
    Sumitani, H
    Okada, S
    ANTICANCER RESEARCH, 1996, 16 (01) : 533 - 535
  • [44] NEOADJUVANT CHEMOTHERAPY RESULTS IN SKELETAL MUSCLE INDEX DECLINE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
    Steinsiek, Nikki
    Acevedo, Ann Martinez
    Guimaraes, Alexander
    Achim, Virginie
    Jones, Paul
    Bash, Jasper
    Whitaker, Makena
    Amling, Christopher L.
    Cetnar, Jeremy
    Liu, Jen-Jane
    JOURNAL OF UROLOGY, 2018, 199 (04): : E531 - E531
  • [45] Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting
    Daiki Ikarashi
    Shigehisa Kitano
    Takashi Tsuyukubo
    Kazumasa Takenouchi
    Takayuki Nakayama
    Hiroko Onagi
    Asumi Sakaguchi
    Makiko Yamashita
    Hidenori Mizugaki
    Shigekatsu Maekawa
    Renpei Kato
    Yoichiro Kato
    Tamotsu Sugai
    Tetsuya Nakatsura
    Wataru Obara
    British Journal of Cancer, 2022, 126 : 606 - 614
  • [46] Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting
    Ikarashi, Daiki
    Kitano, Shigehisa
    Tsuyukubo, Takashi
    Takenouchi, Kazumasa
    Nakayama, Takayuki
    Onagi, Hiroko
    Sakaguchi, Asumi
    Yamashita, Makiko
    Mizugaki, Hidenori
    Maekawa, Shigekatsu
    Kato, Renpei
    Kato, Yoichiro
    Sugai, Tamotsu
    Nakatsura, Tetsuya
    Obara, Wataru
    BRITISH JOURNAL OF CANCER, 2022, 126 (04) : 606 - 614
  • [47] Urine DNA model to predict response to neoadjuvant immune checkpoint inhibitors combined with chemotherapy in muscle-invasive bladder cancer
    Hu, Hailong
    Liu, Huanhuan
    Zhao, Gangjian
    Zhang, Zhe
    Shen, Chong
    Qin, Jiayue
    Cao, Shanbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant, Aaron
    Kates, Max
    Chappidi, Meera R.
    Patel, Hiten D.
    Sopko, Nikolai A.
    Netto, George J.
    Baras, Alex S.
    Hahn, Noah M.
    Pierorazio, Phillip M.
    Bivalacqua, Trinity J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (01) : 34.e17 - 34.e25
  • [49] Cost-effectiveness analysis of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
    Stevenson, Scott M.
    Deibert, Chris M.
    McKiernan, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [50] ETIOLOGY OF TREATMENT DELAYS IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
    El-Arabi, Ahmad
    Sherman, Garth
    Holzbeierlein, Jeffrey
    Lee, Eugene
    Wulff-Burchfield, Elizabeth
    JOURNAL OF UROLOGY, 2019, 201 (04): : E1025 - E1026
12345